NCT06243666 2025-07-31
Long-term Effectiveness and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Preadolescent Girls
Xiamen University
Active not recruiting
Clinical Trials
12 trialsNCT03946358 2024-12-20
VolATIL
Centre Hospitalier Universitaire de Besancon
Phase 2 Completed
NCT03629886 2024-03-15
Safety and Protective Effect Study of GSK Biologicals' Human Papillomavirus (Types 16, 18) Vaccine, Adsorbed (GSK580299) in Healthy Female Subjects From the HPV-039 Study
GlaxoSmithKline
Phase 4 Completed
NCT04704908 2023-01-26
Immuno-persistence Study of a Recombinant Human Papillomavirus 16/18 Bivalent Vaccine in Preadolescent Girls (54m)
Xiamen University
Unknown
NCT04969445 2023-01-26
The Durability of Protection Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
Xiamen University
Unknown
NCT05045755 2023-01-26
The Durability of Protection and Immuno-persistence Study of a Recombinant HPV 16/18 Bivalent Vaccine in Female
Xiamen University
Unknown
NCT05694728 2023-01-23
A Phase II Trial Evaluate the Immunogenicity and Safety Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 2 Completed
NCT05680454 2023-01-17
A Phase I Trial Evaluate the Safety and Tolerability Profile of HPV Vaccine
Beijing Health Guard Biotechnology, Inc
Phase 1 Completed
NCT05662020 2022-12-27
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
Beijing Health Guard Biotechnology, Inc
Phase 3 Active not recruiting
NCT05426148 2022-06-29
Lot Consistency Clinical Trial of of Recombinant HPV Bivalent Vaccine in 9 to14 Years Old Healthy Female
Xiamen Innovax Biotech Co., Ltd
Phase 4 Completed
NCT01031069 2020-07-21
Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
GlaxoSmithKline
Phase 4 Completed
NCT00501137 2015-04-10
BCGov-01
University of British Columbia
Phase 3 Completed